Filing summary: Tivic Health Systems, Inc. — Q3 2023 Form 10-Q
Entity note: The filing provided is for Tivic Health Systems, Inc. (Nasdaq: TIVC), not Valion Bio, Inc. It covers the quarter and nine months ended September 30, 2023; statements are unaudited. Amounts below are in U.S. dollars unless noted.
Business context and reporting period
Tivic develops and commercializes non-invasive bioelectronic medicine. Its commercial product is ClearUP, an FDA-approved sinus pain and congestion device sold online and through resellers. The company also reports research programs involving vagus nerve stimulation and postoperative sinus-surgery pain.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $282,000 | $477,000 | $819,000 | $1.432 million |
| Gross profit | $108,000 | $63,000 | $282,000 | $256,000 |
| Gross margin | 38.3% | 13.2% | 34.4% | 17.9% |
| Operating expenses | $1.868 million | $2.647 million | $6.283 million | $8.098 million |
| Net loss | $1.760 million | $2.584 million | $6.001 million | $7.842 million |
| Operating cash used | — | $6.737 million | $6.692 million |
At September 30, 2023, cash and cash equivalents were $5.169 million, working capital was approximately $5.5 million, total assets were $7.007 million and total liabilities were $1.242 million. Liabilities included $415,000 in operating lease obligations; the filing reports no borrowings outstanding. Accumulated deficit was $35.643 million.
Cash increased $1.652 million over the first nine months, reflecting $8.507 million in financing cash inflows, partly offset by $6.737 million used in operations and $118,000 used for equipment. Management states cash and available resources may not meet anticipated needs for the 12 months following issuance of the financial statements.
Material changes versus the prior comparable period
- Revenue fell 40.9% in Q3 and 42.8% for the nine-month period. Management attributed the decline primarily to higher pricing and reduced marketing, which lowered unit sales; average selling prices rose.
- Gross profit and gross margin improved despite lower revenue. Management cited higher retail pricing and lower manufacturing and fulfillment costs; lower volume also increased fixed cost per unit.
- Operating expenses decreased 29% in Q3 and 22% year to date, mainly from lower general and administrative costs and reduced marketing spend. Year-to-date R&D expense was flat.
- Operating cash use was approximately level year over year, despite the lower reported net loss, with working-capital movements affecting cash flow.
Outlook, commentary, risks and unusual items
- Going concern: The filing says substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance. Tivic expects further losses and says it will need additional capital; availability and terms of future financing are uncertain.
- Commercial plans: Management reported targeted marketing initiatives, a planned InStep Health awareness program expected to reach about 2,500 healthcare professionals, and a distribution agreement with AmerisourceBergen expected to begin sales distribution by year-end 2023. These are forward-looking plans, not reported results.
- Product and R&D: Product improvements addressing charging and battery life were expected to reach the market by Q4 2023. Clinical and research work includes a postoperative-pain trial and a vagus-nerve-stimulation collaboration. No quantitative revenue or earnings guidance is provided.
- Financing and dilution: The company completed common-stock offerings in February and July–August 2023. The latter raised approximately $5.2 million gross and $4.8 million net; placement-agent warrants were also issued. Common shares outstanding rose to 1,466,092 at September 30, 2023, after a 1-for-100 reverse stock split. Share and per-share figures were retrospectively adjusted for the split.
- Nasdaq listing: After a minimum-bid-price deficiency and a delisting determination, the company effected the reverse split and regained compliance on September 15, 2023. It warns that future noncompliance could again threaten its listing and access to capital.
- Other risks: Sales rely on ClearUP and include customer concentration; one customer represented 40% of Q3 revenue. Manufacturing is fully outsourced, and the company cites supply-chain, inflation, macroeconomic, geopolitical, and financing risks. It reports no material pending litigation and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the filing belongs to Tivic Health Systems (TIVC), rather than Valion Bio, Inc.
- Assess the going-concern warning against the company’s cash balance, operating cash burn, and access to additional financing.
- Track whether lower unit sales stabilize and whether pricing, marketing, and new distribution channels improve revenue without eroding margins.
- Review subsequent filings for share issuance, warrant exercises, dilution, and continued Nasdaq listing compliance.
- Check whether the announced distribution, healthcare-awareness, product-improvement, and research milestones occurred as planned.